Voyager Therapeutics, Inc. 8-K

What Happened
Voyager Therapeutics, Inc. (VYGR) filed an 8-K on Feb 12, 2026 announcing that Chief Medical Officer Toby Ferguson, M.D., Ph.D., notified the company on Feb 9, 2026 that he will resign from his CMO role and all company positions effective Feb 20, 2026 to pursue a new opportunity. The filing states his resignation is not the result of any disagreement with the company. The company also disclosed that President and CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will assume key responsibilities, including strategic guidance of the company’s clinical development programs, on an interim basis after the effective date.

Key Details

• Toby Ferguson, M.D., Ph.D., submitted notice to resign on Feb 9, 2026; resignation effective Feb 20, 2026.
• The filing explicitly states the resignation is not due to any disagreement with Voyager.
• CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will take on interim responsibilities for clinical development following the effective date.
• Disclosure made via Form 8-K filed Feb 12, 2026.

Why It Matters
A CMO departure is a material leadership change for a clinical-stage biotech because the role directly affects clinical program oversight and regulatory interactions. Voyager indicates continuity by having its CEO take interim responsibility for clinical strategy, which may reduce near-term disruption. Investors should note the factual timeline and interim coverage; further filings or announcements may follow regarding a permanent CMO appointment or changes to clinical program leadership.